Paul Matteis
Stock Analyst at Stifel
(2.00)
# 3,051
Out of 4,989 analysts
110
Total ratings
40.28%
Success rate
-6.76%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Buy | $30 → $65 | $45.88 | +41.69% | 2 | Sep 24, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $494 → $455 | $374.68 | +21.44% | 19 | Aug 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $166 → $174 | $146.84 | +18.50% | 9 | Jul 31, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $66 → $36 | $13.29 | +170.88% | 4 | Jul 31, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $78 → $94 | $95.87 | -1.95% | 2 | May 29, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 → $345 | $459.58 | -24.93% | 14 | Mar 31, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Hold | $6 → $2 | $1.82 | +10.19% | 2 | Mar 7, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $32 | $26.85 | +19.18% | 1 | Mar 4, 2025 | |
| GHRS GH Research | Maintains: Buy | $18 → $32 | $13.78 | +132.22% | 2 | Feb 27, 2025 | |
| CMPS COMPASS Pathways | Initiates: Buy | $11 | $5.36 | +105.42% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $3.20 | +25.00% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $3.79 | +163.71% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $17.30 | +246.82% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $27.67 | +30.10% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $87 | $53.37 | +63.01% | 8 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $26.71 | +31.04% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $63.51 | -16.55% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $21.56 | -2.60% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $10.31 | +181.28% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $136.38 | +110.44% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.73 | +197.18% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.50 | +242.86% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $2.55 | +841.18% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $360 → $50 | $4.06 | +1,132.62% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $13.06 | +145.02% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.28 | +2,009.38% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $15.60 | -10.26% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $6.69 | +856.65% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $88.14 | +285.75% | 1 | Dec 21, 2016 |
uniQure
Sep 24, 2025
Maintains: Buy
Price Target: $30 → $65
Current: $45.88
Upside: +41.69%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Hold
Price Target: $494 → $455
Current: $374.68
Upside: +21.44%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Buy
Price Target: $166 → $174
Current: $146.84
Upside: +18.50%
Dyne Therapeutics
Jul 31, 2025
Maintains: Buy
Price Target: $66 → $36
Current: $13.29
Upside: +170.88%
Rhythm Pharmaceuticals
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $95.87
Upside: -1.95%
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Buy
Price Target: $300 → $345
Current: $459.58
Upside: -24.93%
Neumora Therapeutics
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $1.82
Upside: +10.19%
Sionna Therapeutics
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $26.85
Upside: +19.18%
GH Research
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $13.78
Upside: +132.22%
COMPASS Pathways
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $5.36
Upside: +105.42%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $3.20
Upside: +25.00%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $3.79
Upside: +163.71%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $17.30
Upside: +246.82%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $27.67
Upside: +30.10%
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $53.37
Upside: +63.01%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $26.71
Upside: +31.04%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $63.51
Upside: -16.55%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $21.56
Upside: -2.60%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $10.31
Upside: +181.28%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $136.38
Upside: +110.44%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $6.73
Upside: +197.18%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $3.50
Upside: +242.86%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $2.55
Upside: +841.18%
Jun 23, 2022
Downgrades: Hold
Price Target: $360 → $50
Current: $4.06
Upside: +1,132.62%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $13.06
Upside: +145.02%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.28
Upside: +2,009.38%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $15.60
Upside: -10.26%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $6.69
Upside: +856.65%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $88.14
Upside: +285.75%